We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

69 hedge funds and large institutions have $35.5M invested in Galectin Therapeutics in 2018 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

50% more capital invested

Capital invested by funds: $23.6M → $35.5M (+$11.8M)

27% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 15

11% more funds holding

Funds holding: 62 → 69 (+7)

0.79% more ownership

Funds ownership: 13.99% → 14.78% (+0.79%)

69% less call options, than puts

Call options by funds: $1.17M | Put options by funds: $3.83M

Holders
69
Holders Change
+7
Holders Change %
+11.29%
% of All Funds
1.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
19
Reduced
15
Closed
11
Calls
$1.17M
Puts
$3.83M
Net Calls
-$2.66M
Net Calls Change
-$2.73M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.91M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.48M
3
Group One Trading
Group One Trading
Illinois
+$503K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$368K
5
AG
Advisor Group
Arizona
+$276K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$630K
2
EI
EAM Investors
California
-$491K
3
BCM
BlueCrest Capital Management
Jersey
-$481K
4
DADC
D.A. Davidson & Co
Montana
-$364K
5
EGI
EAM Global Investors
California
-$305K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$7.67M +$197K +40,441 +3%
DADC
2
D.A. Davidson & Co
Montana
$4.17M -$364K -74,773 -10%
AG
3
Advisor Group
Arizona
$3.9M +$276K +56,587 +10%
BlackRock
4
BlackRock
New York
$3.74M +$1.91M +392,151 +200%
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$2.28M +$1.48M +304,328 +569%
BCA
6
Benchmark Capital Advisors
New York
$1.41M – – –
EI
7
EAM Investors
California
$1.39M -$491K -100,758 -32%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$1.29M +$34.8K +7,152 +4%
EGI
9
EAM Global Investors
California
$1.05M -$305K -62,552 -28%
Group One Trading
10
Group One Trading
Illinois
$690K +$503K +103,339 +2,006%
Millennium Management
11
Millennium Management
New York
$582K -$21.2K -4,348 -5%
Northern Trust
12
Northern Trust
Illinois
$551K +$35.9K +7,362 +9%
Neuberger Berman Group
13
Neuberger Berman Group
New York
$525K – – –
Bank of Montreal
14
Bank of Montreal
Ontario, Canada
$480K +$368K +75,500 New
Morgan Stanley
15
Morgan Stanley
New York
$391K +$83.2K +17,077 +39%
CCB
16
Cutter & Co Brokerage
Missouri
$343K +$1.95K +400 +0.7%
PNC Financial Services Group
17
PNC Financial Services Group
Pennsylvania
$332K +$4.77K +980 +2%
IG
18
ING Group
Netherlands
$318K +$244K +50,000 New
State Street
19
State Street
Massachusetts
$303K +$147K +30,100 +172%
BAM
20
Belpointe Asset Management
Nevada
$277K +$212K +43,556 New
Wells Fargo
21
Wells Fargo
California
$255K +$144K +29,553 +279%
Renaissance Technologies
22
Renaissance Technologies
New York
$237K +$182K +37,300 New
FAAS
23
First Allied Advisory Services
California
$223K +$170K +35,000 New
CAN
24
Cetera Advisor Networks
California
$215K +$164K +33,721 New
ARTA
25
A.R.T. Advisors
New York
$202K -$126K -25,893 -45%
1
2 3 4

GALT Hedge Fund Activity: Q2 2018 in Review

69 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2018, worth a combined $35.5M — up 50% from $23.6M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new GALT positions and 11 closed out — a net gain of 7 holders — while 19 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $1.91M. The largest seller was Sabby Management, cutting an estimated $630K.

  • 69 institutional investors held Galectin Therapeutics (GALT) as of Q2 2018, up from 62 in Q1 2018.
  • Funds reported $35.5M of Galectin Therapeutics stock for Q2 2018, up 50% quarter-over-quarter.
  • 18 funds opened new Galectin Therapeutics positions in Q2 2018 and 11 closed out, a net change of +7 holders.
  • The largest Galectin Therapeutics buyer in Q2 2018 was BlackRock, an estimated $1.91M added.
  • The largest Galectin Therapeutics seller in Q2 2018 was Sabby Management, an estimated $630K sold.

Based on aggregated 13F filings for Q2 2018.